Difference between revisions of "Glofitamab (Columvi)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "/CD3 bispecific" to "-CD3 bispecific") |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 5: | Line 5: | ||
*[[Diffuse large B-cell lymphoma]] | *[[Diffuse large B-cell lymphoma]] | ||
*[[Transformed lymphoma]] | *[[Transformed lymphoma]] | ||
| − | |||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*2023-06-15: Initial accelerated approval for relapsed or refractory [[diffuse large B-cell lymphoma|diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)]] or [[Transformed lymphoma|large B-cell lymphoma (LBCL) arising from follicular lymphoma]], after two or more lines of systemic therapy. ''(Based on NP30179)'' | *2023-06-15: Initial accelerated approval for relapsed or refractory [[diffuse large B-cell lymphoma|diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)]] or [[Transformed lymphoma|large B-cell lymphoma (LBCL) arising from follicular lymphoma]], after two or more lines of systemic therapy. ''(Based on NP30179)'' | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' RO 7082859 | + | *'''Code name:''' RO-7082859 |
*'''Generic name:''' glofitamab-gxbm | *'''Generic name:''' glofitamab-gxbm | ||
*'''Brand name:''' Columvi | *'''Brand name:''' Columvi | ||
| Line 16: | Line 15: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | + | [[Category:Anti-CD20-CD3 bispecific antibodies]] | |
| − | [[Category:Anti-CD20 | ||
| − | |||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
Latest revision as of 00:13, 18 October 2023
Mechanism of action
From the NCI Drug Dictionary: A bispecific monoclonal antibody, with potential antineoplastic activity. Glofitamab contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, glofitamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.
Diseases for which it is used
History of changes in FDA indication
- 2023-06-15: Initial accelerated approval for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. (Based on NP30179)
Also known as
- Code name: RO-7082859
- Generic name: glofitamab-gxbm
- Brand name: Columvi